drugset
drugset / Trial / NCT04620811

An Extension Study of Lirentelimab in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04620811 ↗

Phase 3 Completed 159 enrolled Allakos Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 3, open-label, extension study to assess the long term efficacy and safety of lirentelimab given monthly.

Timeline

Start
2020-12-03
Primary completion
2023-05-15
Completion
2023-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject lirentelimab Monoclonal antibody 3 mg/kg —

Indications

eosinophilic gastritis